$2.6 Billion is the total value of Camber Capital Management LP's 33 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 34.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $271,280,000 | – | 1,000,000 | +100.0% | 10.44% | – |
| AGN | Buy | ALLERGAN PLC | $167,554,000 | +17.1% | 1,005,000 | +18.2% | 6.45% | -8.2% |
| HCA | Buy | HCA HEALTHCARE INC | $138,510,000 | +14.2% | 1,350,000 | +8.0% | 5.33% | -10.5% |
| BIIB | Sell | BIOGEN INC | $130,608,000 | -7.4% | 450,000 | -12.6% | 5.02% | -27.4% |
| GHDX | GENOMIC HEALTH INC | $123,888,000 | +61.1% | 2,458,100 | 0.0% | 4.77% | +26.2% | |
| TSRO | Buy | TESARO INC | $111,175,000 | +12.8% | 2,500,000 | +44.9% | 4.28% | -11.6% |
| BMY | New | BRISTOL MYERS SQUIBB COcall | $110,680,000 | – | 2,000,000 | +100.0% | 4.26% | – |
| SHPG | Sell | SHIRE PLCsponsored adr | $109,720,000 | -33.2% | 650,000 | -40.9% | 4.22% | -47.7% |
| UHS | Buy | UNIVERSAL HLTH SVCS INCcl b | $100,296,000 | +8.6% | 900,000 | +15.4% | 3.86% | -14.9% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $99,440,000 | +71.6% | 2,200,000 | +83.3% | 3.83% | +34.4% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $97,660,000 | -38.7% | 2,000,000 | +33.3% | 3.76% | -52.0% |
| MYL | Buy | MYLAN N V | $90,350,000 | +75.6% | 2,500,000 | +100.0% | 3.48% | +37.6% |
| CELG | New | CELGENE CORPcall | $79,420,000 | – | 1,000,000 | +100.0% | 3.06% | – |
| THC | Sell | TENET HEALTHCARE CORP | $75,533,000 | -26.7% | 2,250,000 | -47.1% | 2.91% | -42.6% |
| MDCO | MEDICINES CO | $73,400,000 | +11.4% | 2,000,000 | 0.0% | 2.82% | -12.7% | |
| EVHC | Sell | ENVISION HEALTHCARE CORP | $72,617,000 | -33.7% | 1,650,000 | -42.1% | 2.79% | -48.0% |
| PRGO | Buy | PERRIGO CO PLC | $67,442,000 | +102.3% | 925,000 | +131.2% | 2.60% | +58.5% |
| NUVA | NUVASIVE INC | $62,544,000 | -0.2% | 1,200,000 | 0.0% | 2.41% | -21.8% | |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $62,475,000 | +2443.8% | 3,055,000 | +2157.9% | 2.40% | +1886.8% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $59,535,000 | -5.6% | 1,620,000 | +0.2% | 2.29% | -26.0% |
| BKD | BROOKDALE SENIOR LIVING | $59,085,000 | +35.5% | 6,500,000 | 0.0% | 2.27% | +6.2% | |
| MYGN | MYRIAD GENETICS INC | $56,055,000 | +26.5% | 1,500,000 | 0.0% | 2.16% | -0.9% | |
| CSII | Buy | CARDIOVASCULAR SYS INC DEL | $53,286,000 | +96.5% | 1,647,677 | +33.3% | 2.05% | +54.0% |
| ELGX | ENDOLOGIX INC | $52,638,000 | +33.8% | 9,300,000 | 0.0% | 2.02% | +4.9% | |
| AMAG | AMAG PHARMACEUTICALS INC | $51,675,000 | -3.2% | 2,650,000 | 0.0% | 1.99% | -24.2% | |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $45,470,000 | +4.4% | 1,000,000 | +21.2% | 1.75% | -18.2% |
| KTWO | Buy | K2M GROUP HLDGS INC | $45,000,000 | +76.0% | 2,000,000 | +48.2% | 1.73% | +37.9% |
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $35,454,000 | – | 1,900,000 | +100.0% | 1.36% | – |
| WMGI | Buy | WRIGHT MED GROUP N V | $32,450,000 | +100.7% | 1,250,000 | +53.4% | 1.25% | +57.3% |
| ENDP | ENDO INTL PLC | $23,575,000 | +58.8% | 2,500,000 | 0.0% | 0.91% | +24.4% | |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $19,755,000 | – | 261,100 | +100.0% | 0.76% | – |
| ZYME | New | ZYMEWORKS INC | $18,475,000 | – | 1,250,000 | +100.0% | 0.71% | – |
| SGRY | SURGERY PARTNERS INC | $2,013,000 | -13.1% | 135,084 | 0.0% | 0.08% | -32.5% | |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -250,000 | -100.0% | -0.45% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -0.47% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -1,500,000 | -100.0% | -1.17% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -1,500,000 | -100.0% | -2.88% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -1,250,000 | -100.0% | -3.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.